Wilkinson et al. investigated three different types of DCs in the peripheral blood of prostate cancer patients (CD11c+CD16-, CD11c+CD16+, CD11c-CD123+) and did not find any significant differences in any DC subset, at any clinical stage of prostate cancer [67]. This evidence concerns the gene ITGAX and prostate carcinoma.